1-20 of 36
Vivek Subbiah
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinico-genomic profiling of conventional and dedifferentiated chondrosarcomas reveals TP53 mutation to be associated with worse outcomes

Ryan A. Denu, Richard K. Yang, Alexander J. Lazar, Shalin S. Patel, Valerae O. Lewis, Jason Roszik, J. Andrew Livingston, Wei-Lien Wang, Kenna R. Shaw, Ravin Ratan, Maria A. Zarzour, Justin Bird, Shaan M. Raza, Kadir C. Akdemir, Jordi Rodon Ahnert, Vivek Subbiah, Shreyaskumar Patel, Anthony P. Conley
Journal: Clinical Cancer Research
Clin Cancer Res (2023)
https://doi.org/10.1158/1078-0432.CCR-23-1703
Published: 25 September 2023
View article titled, Clinico-genomic profiling of conventional and dedifferentiated chondrosarcomas reveals <em>TP53</em> mutation to be associated with worse outcomes
Open the PDF for Clinico-genomic profiling of conventional and dedifferentiated chondrosarcomas reveals <em>TP53</em> mutation to be associated with worse outcomes in another window
Includes: Supplementary data
Journal Articles

The landscape of alterations from 1407 ultra-rare sarcomas from the AACR GENIE database: Clinical implications

Ryan A. Denu, Justin T. Moyers, Mohamed A. Gouda, Anthony Conley, Alexander J. Lazar, Vivek Subbiah
Journal: Clinical Cancer Research
Clin Cancer Res CCR-23-0876.
https://doi.org/10.1158/1078-0432.CCR-23-0876
Published: 29 August 2023
View article titled, The landscape of alterations from 1407 ultra-rare sarcomas from the AACR GENIE database: Clinical implications
Open the PDF for The landscape of alterations from 1407 ultra-rare sarcomas from the AACR GENIE database: Clinical implications in another window
Includes: Supplementary data
Journal Articles

Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

Vivek Subbiah, Sant P. Chawla, Anthony P. Conley, Breelyn A. Wilky, Anthony Tolcher, Nehal J. Lakhani, David Berz, Vasily Andrianov, William Crago, Monica Holcomb, Abrahim Hussain, Carson Veldstra, James Kalabus, Brianne O’Neill, Lane Senne, Emily Rowell, Analeah B. Heidt, Katelyn M. Willis, Brendan P. Eckelman
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (16): 2988–3003.
https://doi.org/10.1158/1078-0432.CCR-23-0974
Published: 15 August 2023
View article titled, Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma
Open the PDF for Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma in another window
Includes: Supplementary data
Journal Articles

Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications

Mohamed A. Gouda, Blessie E. Nelson, Lars Buschhorn, Adam Wahida, Vivek Subbiah
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (15): 2753–2760.
https://doi.org/10.1158/1078-0432.CCR-23-0090
Published: 01 August 2023
View article titled, Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications
Open the PDF for Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications in another window
Includes: Supplementary data
Journal Articles

Direct-to-Patient Clinical Trials: One Small Step or a Giant Leap?

Aakash Desai, Vivek Subbiah
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (13): 2339–2341.
https://doi.org/10.1158/1078-0432.CCR-23-0746
Published: 05 July 2023
View article titled, Direct-to-Patient Clinical Trials: One Small Step or a Giant Leap?
Open the PDF for Direct-to-Patient Clinical Trials: One Small Step or a Giant Leap? in another window
Journal Articles

Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)

Roberto Carmagnani Pestana, Justin T. Moyers, Jason Roszik, Shiraj Sen, David S. Hong, Aung Naing, Cynthia E. Herzog, Siqing Fu, Sarina A. Piha-Paul, Jordi Rodon, Timothy A. Yap, Daniel D. Karp, Apostolia M. Tsimberidou, Shubham Pant, Maria A. Zarzour, Ravin Ratan, Vinod Ravi, Robert S. Benjamin, Alexander J. Lazar, Wei-Lien Wang, Najat Daw, Jonathan B. Gill, Douglas J. Harrison, Valerae O. Lewis, Christina L. Roland, Shreyaskumar R. Patel, J. Andrew Livingston, Neeta Somaiah, Joseph A. Ludwig, Anthony P. Conley, Nelson Hamerschlak, Richard Gorlick, Funda Meric-Bernstam, Vivek Subbiah
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (9): 1708–1718.
https://doi.org/10.1158/1078-0432.CCR-22-3629
Published: 01 May 2023
View article titled, Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)
Open the PDF for Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101) in another window
Includes: Supplementary data
Journal Articles

Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)

Justin T. Moyers, Roberto Carmagnani Pestana, Jason Roszik, David S. Hong, Aung Naing, Siqing Fu, Sarina Piha-Paul, Timothy A. Yap, Daniel Karp, Jordi Rodon, Andy Livingston, Maria Alejandra Zarzour, Vinod Ravi, Shreyaskumar Patel, Robert S. Benjamin, Joseph Ludwig, Cynthia Herzog, Ravin Ratan, Neeta Somaiah, Anthony Conley, Richard Gorlick, Funda Meric-Bernstam, Vivek Subbiah
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (2): 401–409.
https://doi.org/10.1158/1078-0432.CCR-22-2509
Published: 17 January 2023
View article titled, Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)
Open the PDF for Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102) in another window
Includes: Supplementary data
Journal Articles

Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101)

Hani Babiker, Erkut Borazanci, Vivek Subbiah, Sanjiv Agarwala, Alain Algazi, Jacob Schachter, Michael Lotem, Corinne Maurice-Dror, Daniel Hendler, Shah Rahimian, Hans Minderman, Cara Haymaker, Daruka Mahadevan, Chantale Bernatchez, Ravi Murthy, Rolf Hultsch, Nadia Kaplan, Gregory Woodhead, Charles Hennemeyer, Srinivas Chunduru, Peter M. Anderson, Adi Diab, Igor Puzanov
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (23): 5079–5087.
https://doi.org/10.1158/1078-0432.CCR-21-4486
Published: 01 December 2022
View article titled, Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101)
Open the PDF for Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101) in another window
Includes: Supplementary data
Journal Articles

Targeting Ferroptosis Vulnerability in Synovial Sarcoma: Is It All About ME1?

Vivek Subbiah, Boyi Gan
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (16): 3408–3410.
https://doi.org/10.1158/1078-0432.CCR-22-1257
Published: 15 August 2022
View article titled, Targeting Ferroptosis Vulnerability in Synovial Sarcoma: Is It All About ME1?
Open the PDF for Targeting Ferroptosis Vulnerability in Synovial Sarcoma: Is It All About ME1? in another window
Journal Articles

Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation

Florence Atrafi, Oliver Boix, Vivek Subbiah, Jennifer R. Diamond, Sant P. Chawla, Anthony W. Tolcher, Patricia M. LoRusso, Joseph P. Eder, Martin Gutierrez, Kumar Sankhala, Prabhu Rajagopalan, Isabelle Genvresse, Simon Langer, Ron H.J. Mathijssen, Jaap Verweij, Ingmar Bruns, Martijn P. Lolkema
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (13): 2969.
https://doi.org/10.1158/1078-0432.CCR-22-1792
Published: 01 July 2022
View article titled, Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation
Open the PDF for Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation in another window
Journal Articles

Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study

Vivek Subbiah, Irene Braña, Alessandra Longhi, Valentina Boni, Jean-Pierre Delord, Ahmad Awada, Pascaline Boudou-Rouquette, John Sarantopoulos, Geoffrey I. Shapiro, Anthony Elias, Ravin Ratan, Cristian Fernandez, Carmen Kahatt, Martin Cullell-Young, Mariano Siguero, Ali Zeaiter, Sant P. Chawla
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (13): 2762–2770.
https://doi.org/10.1158/1078-0432.CCR-22-0696
Published: 01 July 2022
View article titled, Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study
Open the PDF for Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study in another window
Journal Articles

A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation

Florence Atrafi, Oliver Boix, Vivek Subbiah, Jennifer R. Diamond, Sant P. Chawla, Anthony W. Tolcher, Patricia M. LoRusso, Joseph P. Eder, Martin Gutierrez, Kumar Sankhala, Prabhu Rajagopalan, Isabelle Genvresse, Simon Langer, Ron H.J. Mathijssen, Jaap Verweij, Ingmar Bruns, Martijn P. Lolkema
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (23): 6366–6375.
https://doi.org/10.1158/1078-0432.CCR-20-4185
Published: 01 December 2021
View article titled, A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation
Open the PDF for A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation in another window
Includes: Supplementary data
Journal Articles

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

Vivek Subbiah, Justin F. Gainor, Geoffrey R. Oxnard, Daniel S.W. Tan, Dwight H. Owen, Byoung Chul Cho, Herbert H. Loong, Caroline E. McCoach, Jared Weiss, Yu Jung Kim, Lyudmila Bazhenova, Keunchil Park, Haruko Daga, Benjamin Besse, Oliver Gautschi, Christian Rolfo, Edward Y. Zhu, Jennifer F. Kherani, Xin Huang, Suhyun Kang, Alexander Drilon
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (15): 4160–4167.
https://doi.org/10.1158/1078-0432.CCR-21-0800
Published: 01 August 2021
View article titled, Intracranial Efficacy of Selpercatinib in <em>RET</em> Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial
Open the PDF for Intracranial Efficacy of Selpercatinib in <em>RET</em> Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial in another window
Includes: Supplementary data
Journal Articles

First-in-Human Phase I Study of ABBV-085, an Antibody–Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors

George D. Demetri, Jason J. Luke, Antoine Hollebecque, John D. Powderly, II, Alexander I. Spira, Vivek Subbiah, Louie Naumovski, Chris Chen, Hua Fang, Dominic W. Lai, Huibin Yue, Akshanth R. Polepally, James W. Purcell, Randy Robinson, Padmanee Sharma, James P. Allison, Anthony Tolcher, Victor M. Villalobos
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (13): 3556–3566.
https://doi.org/10.1158/1078-0432.CCR-20-4513
Published: 01 July 2021
View article titled, First-in-Human Phase I Study of ABBV-085, an Antibody–Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors
Open the PDF for First-in-Human Phase I Study of ABBV-085, an Antibody–Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies

Aparna Hegde, Priyamvada Jayaprakash, Coline A. Couillault, Sarina Piha-Paul, Daniel Karp, Jordi Rodon, Shubham Pant, Siqing Fu, Ecaterina E. Dumbrava, Timothy A. Yap, Vivek Subbiah, Priya Bhosale, Cristian Coarfa, Jack P. Higgins, Eric T. Williams, Thomas F. Wilson, JoAnn Lim, Funda Meric-Bernstam, Elizabeth Sumner, Hira Zain, Di Nguyen, Ly M. Nguyen, Kimal Rajapakshe, Michael A. Curran, David S. Hong
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (11): 3050–3060.
https://doi.org/10.1158/1078-0432.CCR-20-4118
Published: 01 June 2021
View article titled, A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies
Open the PDF for A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies in another window
Includes: Supplementary data
Journal Articles

Combination Therapies for Precision Oncology: The Ultimate Whack-A-Mole Game

Roman Groisberg, Vivek Subbiah
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (10): 2672–2674.
https://doi.org/10.1158/1078-0432.CCR-21-0254
Published: 15 May 2021
View article titled, Combination Therapies for Precision Oncology: The Ultimate Whack-A-Mole Game
Open the PDF for Combination Therapies for Precision Oncology: The Ultimate Whack-A-Mole Game in another window
Journal Articles

Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor−positive Metastatic Breast Cancer or Other Solid Tumors

Alexej Ballhausen, Jennifer J. Wheler, Daniel D. Karp, Sarina A. Piha-Paul, Siqing Fu, Shubham Pant, Apostolia M. Tsimberidou, David S. Hong, Vivek Subbiah, Veronica R. Holley, Helen J. Huang, Abenaa M. Brewster, Kimberly B. Koenig, Nuhad K. Ibrahim, Funda Meric-Bernstam, Filip Janku
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (5): 1247–1255.
https://doi.org/10.1158/1078-0432.CCR-20-2878
Published: 01 March 2021
View article titled, Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor−positive Metastatic Breast Cancer or Other Solid Tumors
Open the PDF for Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor−positive Metastatic Breast Cancer or Other Solid Tumors in another window
Journal Articles

Progresses Toward Precision Medicine in RET-altered Solid Tumors

Carmen Belli, Santosh Anand, Justin F. Gainor, Frederique Penault-Llorca, Vivek Subbiah, Alexander Drilon, Fabrice Andrè, Giuseppe Curigliano
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (23): 6102–6111.
https://doi.org/10.1158/1078-0432.CCR-20-1587
Published: 01 December 2020
View article titled, Progresses Toward Precision Medicine in <em>RET</em>-altered Solid Tumors
Open the PDF for Progresses Toward Precision Medicine in <em>RET</em>-altered Solid Tumors in another window
Journal Articles

Phase I Study of P-cadherin–targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors

Vivek Subbiah, William Erwin, Osama Mawlawi, Asa McCoy, David Wages, Catherine Wheeler, Carlos Gonzalez-Lepera, Holly Liu, Homer Macapinlac, Funda Meric-Bernstam, David S. Hong, Shubham Pant, Dao Le, Elmer Santos, Jose Gonzalez, Jason Roszik, Takeaki Suzuki, Ruth Ann Subach, Timothy Madden, Mary Johansen, Fumiko Nomura, Hirokazu Satoh, Tadashi Matsuura, Masamichi Kajita, Eri Nakamura, Yuichi Funase, Satoshi Matsushima, Gregory Ravizzini
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (22): 5830–5842.
https://doi.org/10.1158/1078-0432.CCR-20-0037
Published: 13 November 2020
View article titled, Phase I Study of P-cadherin–targeted Radioimmunotherapy with <sup>90</sup>Y-FF-21101 Monoclonal Antibody in Solid Tumors
Open the PDF for Phase I Study of P-cadherin–targeted Radioimmunotherapy with <sup>90</sup>Y-FF-21101 Monoclonal Antibody in Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Filip Janku, Haeseong Park, S. Greg Call, Kiran Madwani, Yasuhiro Oki, Vivek Subbiah, David S. Hong, Aung Naing, Vivianne M. Velez-Bravo, Tamara G. Barnes, Fredrick B. Hagemeister, Gerald S. Falchook, Daniel D. Karp, Jennifer J. Wheler, Sarina A. Piha-Paul, Ignacio Garrido-Laguna, Elizabeth J. Shpall, Luis E. Fayad, Sattva S. Neelapu, Funda Meric-Bernstam, Razelle Kurzrock, Michelle A. Fanale
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (21): 5579–5587.
https://doi.org/10.1158/1078-0432.CCR-20-1215
Published: 02 November 2020
View article titled, Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma
Open the PDF for Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma in another window
Includes: Supplementary data